Chronic Heart Failure Clinical Trial
Official title:
Prevalence, Incidence and Clinical Characteristics of Sleep Disordered Breathing in Patients With Stable Chronic Heart Failure
Only few prospective studies systematically investigated the prevalence of sleep disordered breathing in patients with stable chronic heart failure. Furthermore there is no report on the incidence rate of sleep disordered breathing in this population. This is a prospective multi-centre study of sleep-disordered breathing in 200 patients with stable moderate-to-severe chronic heart failure. Eligible patients will undergo overnight full-night polysomnography, lung function testing, laboratory measurements, and hemodynamic recordings. Measurements will be repeated at 6 months interval for a follow-up period of two years irrespective of the presence or absence of sleep disordered breathing. The primary outcome variable for this study is the prevalence of sleep disordered breathing in the study population. Secondary outcome variables include the 2-year incidence rate of sleep disordered breathing, quality of life measurements, exercise capacity, sleep quality, hemodynamic measurements, and laboratory markers of neurohumoral activation, systemic inflammation, and endothelial function in the study population.
Chronic heart failure is a complex clinical syndrome that can result from any structural or
functional cardiac or non-cardiac disorder that impairs the ability of the heart to respond
to physiological demands for increased cardiac output. Chronic heart failure is
characterised by symptoms such as exertional breathlessness and fatigue, and signs of fluid
retention as well as signs associated with the underlying cardiac disorder. Patients with
chronic heart failure suffer from reduced quality of life and a significantly higher risk of
morbidity and mortality.
There is cumulating evidence of a high prevalence of sleep breathing disorders in both
patients with acute and chronic heart failure. Most of these reports, however, suffer from
important limitations including small sample size, retrospective study design, and/or use of
pulse-oximetry or cardio-respiratory polygraphy to screen for sleep disordered breathing
rather than full-night polysomnography. Hence, previous studies may have underestimated the
full scale of concomitant sleep disordered breathing in patients with chronic heart failure.
Furthermore, to the best of our knowledge, there is no report on the incidence of sleep
disordered breathing in patients with chronic heart failure.
In this context the presence of sleep disordered breathing in patients with chronic heart
failure has important prognostic relevance. Pathophysiological effects of sleep apnea
include intermittent hypoxia, sympathetic hyperactivity, systemic inflammation, and sleep
fragmentation. These factors may contribute to the worsening of cardiac function and explain
the reportedly higher risk of cardiac morbidity and mortality in patients with both chronic
heart failure and concomitant sleep disordered breathing. Accordingly, the aims of the
present study are three-fold. First, to investigate the prevalence of sleep breathing
disorders in patients with stable moderate-to-severe chronic heart failure using the
diagnostic gold standard of full-night-polysomnography. Second, to assess the two-year
incidence of sleep disordered breathing in patients with chronic heart failure. Third, to
identify potential risk factors associated with the presence or absence of sleep disordered
breathing in patients with chronic heart failure. The latter will be assessed by using lung
function measurements, hemodynamic parameters, and laboratory markers of neurohumoral
activation, systemic inflammation, and endothelial function in patients with chronic heart
failure.
For this purpose 200 patients with stable moderate-to-severe chronic heart failure will be
studied during a 2 year-period. Patients with chronic heart failure will be screened for
eligibility during their regular visits at 4 independent heart failure outpatients clinic in
Vienna. Eligible patients will undergo full-night-polysomnography, lung function testing,
non-invasive hemodynamic monitoring, a six minute-walking-test, and laboratory measurements
at 6 months intervals for a total of 2 years (4 visits).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|
||
Not yet recruiting |
NCT06002321 -
Right Ventricular Dysfunction in Chronic Heart Failure
|